NRG1-Fusion Lung Adenocarcinoma With a Partial Response to Afatinib

Patient Info: Anonymized, female, 50s

Biomarkers: CD74-NRG1 fusion

Afatinib produced a partial response lasting 24 weeks, with progression after 32 weeks on treatment. She died in April 2022.

PubMed CentralRead more →

How We Got Here: 6 Young Lung Cancer Patients & Their Paths To Surgery- Part 1

Patient Info: Leah Phillips, Female | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: bone (pelvis; spine; ribs)

As of April 2025, Leah was living with Stage IV EGFR exon 19 deletion lung cancer while continuing Tagrisso after SBRT and right middle lobe lobectomy.

YouTube (JA search)Read more →

Lung Squamous Cell Carcinoma Discovered During Severe Disseminated Fungal Infection

Patient Info: Anonymized, male, 50s

He died shortly after discharge after recurrent infection progressed to shock, worsening hypoxemia, and liver and kidney failure.

PubMed CentralRead more →

Stage IV Lung Adenocarcinoma Presenting as Persistent Chest Pain and Rib Metastasis

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: TP53 mutation; PD-L1 30%; no sensitive driver mutation identified

Metastatic Site: bone

After delayed diagnosis of Stage IV lung adenocarcinoma with a painful rib metastasis, he began systemic immunotherapy and local treatment for the painful bone lesion.

PubMed CentralRead more →

Preoperative Stage IIB lung adenocarcinoma: no recurrence after robotic surgery

Patient Info: Anonymized, Female, 60s

As of April 2025, 6-month chest CT showed no recurrence after robotic right lower lobectomy and mediastinal lymph node dissection; no additional chemotherapy or radiation was reported.

PubMed CentralRead more →

Metastatic SMARCA4-Deficient Lung Cancer Controlled for More Than Two Years With Tislelizumab and Fruquintinib

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 8%; no target-sensitive mutation identified

Metastatic Site: left adrenal gland, cervical lymph nodes

After radiotherapy reduced the cervical-node metastasis, imaging on April 26, 2024 showed stable disease. He ended trial treatment after 2 years and continued regular follow-up.

PubMed CentralRead more →

Synchronous Stage I lung adenocarcinomas: VATS surgery with clear margins

Patient Info: Anonymized, Male, 70+

He completed surgical treatment with negative lymph nodes and clear margins, was discharged on postoperative day 9, and was planned for surveillance with his respiratory physician.

PubMed CentralRead more →

Stage IIIA double ALK-fusion lung adenocarcinoma: major pathological response to neoadjuvant alectinib

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: ALK-rearranged lung adenocarcinoma with both ELMOD3-ALK and EML4-ALK fusions. CEA/NSE/CA19-9 decreased after alectinib.

As of April 2025, he had continued alectinib for 4 years after surgery, with more than 48 months of disease-free survival, no recurrence, and no serious drug-related toxicity.

PubMed CentralRead more →

Metastatic lung squamous cell carcinoma: no recurrence after chemoimmunotherapy and pembrolizumab maintenance

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; PD-L1 TPS 95%; TTF-1-negative; p40-positive

Metastatic Site: mediastinal lymph nodes; bilateral lung nodules

As of April 2025, PET/CT 3 years after treatment initiation showed no sign of recurrence after carboplatin, nab-paclitaxel, pembrolizumab, and 2 years of pembrolizumab monotherapy.

PubMed CentralRead more →

Stage IV squamous lung cancer: partial response complicated by pulmonary artery pseudoaneurysm

Patient Info: Anonymized, Male, 60s | Stage IV

Metastatic Site: distant sites not specified (M1c1)

As of April 2025, tumor imaging showed partial remission/significant reduction, and the pulmonary artery pseudoaneurysm was successfully embolized with no recurrent hemoptysis over 6 months.

PubMed CentralRead more →

Metastatic lung adenocarcinoma: pembrolizumab response complicated by pulmonary arterial hypertension

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: CK7-positive; TTF-1-positive; p40 focally positive; high tumor mutational burden; no targetable mutations identified

Metastatic Site: right axillary lymph node; right hilar lymph nodes;…

As of April 2025, the patient was tolerating single-agent pemetrexed without evidence of lung cancer progression, while pulmonary arterial hypertension symptoms had improved on riociguat and macitentan.

PubMed CentralRead more →

Stage III Lung Squamous Cell Carcinoma Diagnosed After Months of COPD-Like Symptoms

Patient Info: Anonymized, male, 40s | Stage III

He died 6 months after his lung-cancer diagnosis from pneumonia complicated by COPD that did not respond to targeted antibiotic treatment.

PubMed CentralRead more →

Lung cancer with a rare kidney inflammation, successfully treated with steroids and radiation

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: EGFR mutation-negative; TTF-1-positive; CK7-positive; CK20-negative

Radiation produced significant tumor regression, and he remained alive without progression of lung cancer or kidney disease for 5 years after discharge.

PubMed CentralRead more →

Stage III Large-Cell Lung Carcinoma Found During Recurrent Pneumonia in a Woman With COPD

Patient Info: Anonymized, female, 50s | Stage III

She died 17 days after the lung-cancer diagnosis while being treated for recurrent pneumonia complicated by COPD.

PubMed CentralRead more →

Small-Cell Lung Cancer With Later Brain and Other Metastases in a Woman With COPD

Patient Info: Anonymized, female, 50s | Stage IV

Metastatic Site: central nervous system

Her neurologic condition progressively worsened after immune-related encephalitis and extensive metastatic progression. She died from sepsis 8 months after the lung-cancer diagnosis.

PubMed CentralRead more →

Small Cell Lung Cancer That Spread to the Ear Canal

Patient Info: Anonymized, male, 70+ | Stage IV

Metastatic Site: external auditory canal, middle ear, pancreas, bone

The metastatic lesions initially shrank and his hearing and ear pain improved, but he died 15 months after diagnosis.

PubMed CentralRead more →

Stage 4 ALK-rearranged lung cancer: complete response with alectinib and SBRT

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Initial tumor: EML4-ALK fusion, EGFR wild type. Later tumor: EGFR L858R/T790M and TP53 L194R, without ALK rearrangement.

Metastatic Site: pleura, lymph nodes

As of March 2025, the original ALK-rearranged metastatic disease had responded to alectinib, the separate EGFR-mutant right upper-lobe lesion had responded to SBRT, and PET-CT showed no hypermetabolic lung lesion.

PubMed CentralRead more →

Stage 4 SMARCA4-deficient lung cancer: ongoing treatment response

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: SMARCA4-deficient lung cancer with BRG-1 loss, CK/CK7 positive, Ki-67 >40%. CEA

Metastatic Site: sigmoid colon, left adrenal gland

After colon metastasis surgery, continued radiotherapy, and later gemcitabine/nedaplatin/bevacizumab/camrelizumab for adrenal metastasis, the cancer showed a favorable response with no further recurrence or new metastasis reported.

PubMed CentralRead more →

Stage II Lung Squamous Cell Carcinoma Complicated by Immunotherapy-Induced Cutaneous Lupus

Patient Info: Anonymized, male, 60s | Stage II

Imaging showed a treatment response. After radical radiotherapy, camrelizumab was discontinued because of immune-mediated subacute cutaneous lupus, and the lung cancer was placed under active monitoring.

PubMed CentralRead more →

Clinical Stage IB lung adenocarcinoma: no recurrence after thoracoscopic lobectomy and pneumatocele repair

Patient Info: Anonymized, Male, 60s | Stage I

Biomarkers: No molecular biomarkers reported; tumor markers were normal: CEA 2.1 ng/mL, SCC antigen 1.5 ng/mL, cytokeratin 19 fragment 0.9 ng/mL

As of March 2025, the patient had no recurrence after thoracoscopic left lower lobectomy for lung adenocarcinoma; postoperative pneumatocele-related air leak resolved with reinforcement and adhesive therapy.

PubMed CentralRead more →

Localized lung adenocarcinoma: disease-free after CT-guided marking and VATS wedge resection

Patient Info: Anonymized, Female, 50s

Biomarkers: No lung molecular biomarkers reported; prior malignant melanoma had BRAF codon 600 mutation

As of March 2025, she remained free of signs of lung cancer recurrence after CT-guided marking, VATS wedge resection, and mediastinal lymph node sampling.

PubMed CentralRead more →

Stage 3 squamous cell lung cancer: complete remission on tislelizumab monotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Squamous lung cancer markers: P40 positive, TTF-1/Napsin A negative, Ki-67 75%. PD-1/PD-L1 testing was not done.

As of April 2024, enhanced CT, tumor-marker decline, and clinical assessment supported complete remission by iRECIST after chemoimmunotherapy and tislelizumab monotherapy.

PubMed CentralRead more →

Severe Autoimmune Hemolytic Anemia After Pembrolizumab for Metastatic Lung Cancer

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 70%

Metastatic Site: left adrenal gland, subdiaphragmatic region

He recovered clinically from the acute hemolytic anemia after intravenous immunoglobulin, high-dose steroids, and blood transfusions, then continued outpatient oncology follow-up.

PubMed CentralRead more →

Metastatic lung adenocarcinoma: complete remission on nivolumab complicated by immune-mediated diabetes

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Lung tumor: EGFR wild type, ALK rearrangement not detected. Immune-mediated diabetes: islet/GAD antibodies negative and C-peptide undetectable.

Metastatic Site: brain (cerebellum and occipital lobe); liver

As of March 2025, serial CT and MRI scans through October 2023 showed no evidence of oncologic disease after nivolumab, while immune-mediated diabetes was controlled with basal-bolus insulin.

PubMed CentralRead more →